Displaying publications 1 - 20 of 207 in total

Abstract:
Sort:
  1. Nur Munirah I, Chidambaram SK
    Med J Malaysia, 2022 01;77(1):92-94.
    PMID: 35087002
    Spontaneous pneumomediastinum is a rare condition in viral pneumonia. However, it can arise spontaneously in COVID-19 patients with no other risk factors. Here we present four cases of spontaneous pneumomediastinum in patients with COVID-19 pneumonia with no other precipitating factors.
    Matched MeSH terms: Pneumonia, Viral*
  2. Chiang CY, Islam T, Xu C, Chinnayah T, Garfin AMC, Rahevar K, et al.
    Eur Respir J, 2020 10;56(4).
    PMID: 32978310 DOI: 10.1183/13993003.03054-2020
    Matched MeSH terms: Pneumonia, Viral*
  3. Chase JG, Chiew YS, Lambermont B, Morimont P, Shaw GM, Desaive T
    Crit Care, 2020 07 10;24(1):415.
    PMID: 32650807 DOI: 10.1186/s13054-020-03152-6
    Matched MeSH terms: Pneumonia, Viral*
  4. Schwalbe N, Lehtimaki S, Gutiérrez JP
    Lancet Glob Health, 2020 08;8(8):e974-e975.
    PMID: 32553131 DOI: 10.1016/S2214-109X(20)30276-X
    Matched MeSH terms: Pneumonia, Viral/epidemiology*
  5. Baticulon RE, Nga VDW, Sobana M, Bahuri NFA, Wittayanakorn N
    World Neurosurg, 2020 12;144:332.
    PMID: 33227873 DOI: 10.1016/j.wneu.2020.09.086
    Matched MeSH terms: Pneumonia, Viral*
  6. Zhiqin W, Muhammad Nawawi KN, Raja Ali RA
    Endoscopy, 2020 08;52(8):704-705.
    PMID: 32722836 DOI: 10.1055/a-1168-6841
    Matched MeSH terms: Pneumonia, Viral*
  7. Chase JG, Chiew YS, Lambermont B, Morimont P, Shaw GM, Desaive T
    Am J Respir Crit Care Med, 2020 11 01;202(9):1316-1317.
    PMID: 32744454 DOI: 10.1164/rccm.202006-2420LE
    Matched MeSH terms: Pneumonia, Viral*
  8. Kow CS, Hasan SS
    Intensive Care Med, 2020 10;46(10):1956-1957.
    PMID: 32638046 DOI: 10.1007/s00134-020-06172-6
    Matched MeSH terms: Pneumonia, Viral/epidemiology*
  9. Kow CS, Hasan SS
    Clin Drug Investig, 2020 10;40(10):989-990.
    PMID: 32816219 DOI: 10.1007/s40261-020-00961-z
    Matched MeSH terms: Pneumonia, Viral*
  10. Ng KH, Kemp R
    J Zhejiang Univ Sci B, 2020 9 8;21(9):752-754.
    PMID: 32893533 DOI: 10.1631/jzus.B2000228
    The world is now plagued by a pandemic of unprecedented nature caused by a novel, emerging, and still poorly understood infectious disease, coronavirus disease 2019 (COVID-19) (Wu and McGoogan, 2020). In addition to the rapidly growing body of scientific and medical literature that is being published, extensive public reports and stories in both the traditional media and social media have served to generate fear, panic, stigmatization, and instances of xenophobia (Zarocostas, 2020).
    Matched MeSH terms: Pneumonia, Viral/epidemiology; Pneumonia, Viral/psychology*
  11. Mahmood Y, Ishtiaq S, Khoo MBC, Teh SY, Khan H
    Int J Qual Health Care, 2021 Apr 16;33(2).
    PMID: 33822932 DOI: 10.1093/intqhc/mzab062
    BACKGROUND: At the end of December 2019, the world in general and Wuhan, the industrial hub of China, in particular, experienced the COVID-19 pandemic. Massive increment of cases and deaths occurred in China and 209 countries in Europe, America, Australia, Asia and Pakistan. Pakistan was first hit by COVID-19 when a case was reported in Karachi on 26 February 2020. Several methods were presented to model the death rate due to the COVID-19 pandemic and to forecast the pinnacle of reported deaths. Still, these methods were not used in identifying the first day when Pakistan enters or exits the early exponential growth phase.

    OBJECTIVE: The present study intends to monitor variations in deaths and identify the growth phases such as pre-growth, growth, and post-growth phases in Pakistan due to the COVID-19 pandemic.

    METHODS: New approaches are needed that display the death patterns and signal an alarming situation so that corrective actions can be taken before the condition worsens. To meet this purpose, secondary data on daily reported deaths due to the COVID-19 pandemic have been considered, and the $c$ and exponentially weighted moving average (EWMA) control charts are used To meet this purpose, secondary data on daily reported deaths in Pakistan due to the COVID-19 pandemic have been considered. The $ c$ and exponentially weighted moving average (EWMA) control charts have been used for monitoring variations.

    RESULTS: The chart shows that Pakistan switches from the pre-growth to the growth phase on 31 March 2020. The EWMA chart demonstrates that Pakistan remains in the growth phase from 31 March 2020 to 17 August 2020, with some indications signaling a decrease in deaths. It is found that Pakistan moved to a post-growth phase for a brief period from 27 July 2020 to 28 July 2020. Pakistan switches to re-growth phase with an alarm on 31/7/2020, right after the short-term post-growth phase. The number of deaths starts decreasing in August in that Pakistan may approach the post-growth phase shortly.

    CONCLUSION: This amalgamation of control charts illustrates a systematic implementation of the charts for government leaders and forefront medical teams to facilitate the rapid detection of daily reported deaths due to COVID-19. Besides government and public health officials, it is also the public's responsibility to follow the enforced standard operating procedures as a temporary remedy of this pandemic in ensuring public safety while awaiting a suitable vaccine to be discovered.

    Matched MeSH terms: Pneumonia, Viral/mortality*; Pneumonia, Viral/virology
  12. Md Noh MSF
    J Neuroradiol, 2020 Sep;47(5):329-330.
    PMID: 32444286 DOI: 10.1016/j.neurad.2020.05.004
    Matched MeSH terms: Pneumonia, Viral/epidemiology
  13. Jayaraj R, Kumarasamy C, Shetty SS, Ram M R, Shaw P
    J Infect, 2020 10;81(4):647-679.
    PMID: 32407756 DOI: 10.1016/j.jinf.2020.05.011
    Matched MeSH terms: Pneumonia, Viral/epidemiology*
  14. Abdullah S, Mansor AA, Napi NNLM, Mansor WNW, Ahmed AN, Ismail M, et al.
    Sci Total Environ, 2020 Aug 10;729:139022.
    PMID: 32353722 DOI: 10.1016/j.scitotenv.2020.139022
    An outbreak of respiratory illness which is proven to be infected by a 2019 novel coronavirus (2019-nCoV) officially named as Coronavirus Disease 2019 (COVID-19) was first detected in Wuhan, China and has spread rapidly in other parts of China as well as other countries around the world, including Malaysia. The first case in Malaysia was identified on 25 January 2020 and the number of cases continue to rise since March 2020. Therefore, 2020 Malaysia Movement Control Order (MCO) was implemented with the aim to isolate the source of the COVID-19 outbreak. As a result, there were fewer number of motor vehicles on the road and the operation of industries was suspended, ergo reducing emissions of hazardous air pollutants in the atmosphere. We had acquired the Air Pollutant Index (API) data from the Department of Environment Malaysia on hourly basis before and during the MCO with the aim to track the changes of fine particulate matter (PM2.5) at 68 air quality monitoring stations. It was found that the PM2.5 concentrations showed a high reduction of up to 58.4% during the MCO. Several red zone areas (>41 confirmed COVID-19 cases) had also reduced of up to 28.3% in the PM2.5 concentrations variation. The reduction did not solely depend on MCO, thus the researchers suggest a further study considering the influencing factors that need to be adhered to in the future.
    Matched MeSH terms: Pneumonia, Viral*
  15. Borzée A, McNeely J, Magellan K, Miller JRB, Porter L, Dutta T, et al.
    Trends Ecol Evol, 2020 12;35(12):1052-1055.
    PMID: 33097287 DOI: 10.1016/j.tree.2020.10.001
    Zoonosis-based epidemics are inevitable unless we revisit our relationship with the natural world, protect habitats, and regulate wildlife trade, including live animals and non-sustenance products. To prevent future zoonoses, governments must establish effective legislation addressing wildlife trade, protection of habitats, and reduction of the wildlife-livestock-human interface.
    Matched MeSH terms: Pneumonia, Viral*
  16. Rabby MII, Hossain F
    Sao Paulo Med J, 2020 8 20;138(5):441-456.
    PMID: 32813843 DOI: 10.1590/1516-3180.2020.0208.R1.15062020
    BACKGROUND: The dangerous SARS-CoV-2 virus first emerged in China in December 2019 and has rapidly spread worldwide. Currently, it has affected more than 2,850,000 people. No vaccine or drug is available yet, and therefore researchers and scientists are striving to identify potential drugs or vaccines for combating this virus. We were unable to find any review of the literature or analysis on ongoing registered clinical trials that reported diagnostic tests, therapeutics, vaccines and devices for COVID-19 along with estimated enrollment, participants' ages, study type, start and completion date, status, treatment/intervention and country.

    OBJECTIVE: To review ongoing trials relating to COVID-19.

    METHODS: A systematic search for clinical trials was conducted in the ClinicalTrials.gov database up to April 12, 2020. A total of 339 trials relating to COVID-19 were analyzed and key information on each trial was recorded.

    RESULTS: Most of the trials were being conducted in the United States and completion of most of them was expected by May 2020. They were mostly on drugs and treatment, while a minority were on diagnostic tests. The analysis showed that hydroxychloroquine was investigated in most of the trials. The trials identified were categorized into five classes: a) diagnostic tests; b) therapeutics; c) biologics and vaccines; d) devices and products; and e) others.

    CONCLUSION: The trials identified have potential against COVID-19 that can be applied in treatment processes after the necessary investigations and experiments. Additionally, the items identified were organized in a proper way, which can assist in current research activities.

    Matched MeSH terms: Pneumonia, Viral*
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links